{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:32:21Z","timestamp":1790677941224,"version":"4.1.0"},"reference-count":199,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.autrev.2017.07.012","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T09:23:29Z","timestamp":1499765009000},"page":"911-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":122,"title":["International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?"],"prefix":"10.1016","volume":"16","author":[{"given":"Roberto","family":"Giacomelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Afeltra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Alunno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bartoloni-Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onorina","family":"Berardicurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saviana","family":"Gandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariele","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Lories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Lunardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Paolo Emanuele","family":"Margiotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Pendolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Olivier","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Priori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Puppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Quartuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Ruffatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Somarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Romana","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Triolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Valesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Vettori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.07.012_bb0005","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.012_bb0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1741-7015-11-100","article-title":"Requirements for innate immune pathways in environmentally induced autoimmunity","volume":"11","author":"Pollard","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.autrev.2015.08.008","article-title":"Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center","volume":"15","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.012_bb0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.autrev.2016.01.016","article-title":"Genetic factors and systemic sclerosis","volume":"15","author":"Murdaca","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2017.07.012_bb0025","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.autrev.2017.01.014","article-title":"Effects of targeted therapies on the bone in arthritides","volume":"16","author":"Szentp\u00e9tery","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0035","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.clinthera.2014.01.014","article-title":"Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms","volume":"36","author":"Cipriani","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0040","first-page":"E839","article-title":"AGREE II: advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010"},{"key":"10.1016\/j.autrev.2017.07.012_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.6370","article-title":"Update of the EULAR recommendations for the management of early arthritis","author":"Combe","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0055","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/annrheumdis-2013-203843","article-title":"Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0070","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/ard.2010.132134","article-title":"Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis","volume":"70","author":"Salliot","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0075","first-page":"333","article-title":"Efficacy of biologic agents in improving the health assessment questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons","volume":"32","author":"Barra","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0080","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/rheumatology\/ket266","article-title":"Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis","volume":"52","author":"Callhoff","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0085","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.semarthrit.2013.11.006","article-title":"The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis","volume":"43","author":"Favalli","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0090","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jbspin.2012.09.023","article-title":"Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate","volume":"80","author":"Pierreisnard","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2017.07.012_bb0095","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"Frazier-Mironer","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2017.07.012_bb0100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3899\/jrheum.111125","article-title":"Longterm retention of tumor necrosis factor-\u03b1 inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors","volume":"39","author":"Iannone","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0105","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","article-title":"TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice","volume":"1173","author":"Marchesoni","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2017.07.012_bb0110","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0115","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kev374","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","author":"Souto","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0120","article-title":"The 12-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","author":"Favalli","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.07.012_bb0125","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1002\/ddr.21192","article-title":"Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides","volume":"75","author":"Biggioggero","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.autrev.2017.07.012_bb0130","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/art.39595","article-title":"Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: results from the Pan-European registry analysis","volume":"68","author":"Gottenberg","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0135","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10067-013-2303-6","article-title":"Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry","volume":"32","author":"Hor\u00e1k","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0140","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1136\/annrheumdis-2015-207760","article-title":"Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study","volume":"75","author":"Gabay","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0145","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","article-title":"Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register","volume":"54","author":"Forsblad-d'Elia","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.012_bb0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2011-201282","article-title":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","volume":"72","author":"Dougados","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0155","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"ADACTA study investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.07.012_bb0160","first-page":"41","article-title":"Management of rheumatoid arthritis patients with interstitial lung disease: safety of biological antirheumatic drugs and assessment of pulmonary fibrosis","volume":"9","author":"Mori","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0165","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","article-title":"Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review","volume":"43","author":"Roubille","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2017.07.012_bb0170","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/ket233","article-title":"The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","volume":"52","author":"Furst","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2008.08.002","article-title":"Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures\u2014a pooled analysis from three large, multicenter, double-blind, randomized clinical trials","volume":"39","author":"Doyle","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098202","article-title":"Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis","volume":"9","author":"Hashimoto","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.012_bb0185","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/ar4397","article-title":"Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis","volume":"15","author":"Isaacs","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0190","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar4323","article-title":"Comparative evaluation of the effects of treatment with tocilizumab and TNF-\u03b1 inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0195","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/acr.20689","article-title":"Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the autoimmunity and rituximab registry","volume":"64","author":"Pu\u00e9chal","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010455.pub2","article-title":"Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","author":"van Herwaarden","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0205","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00296-015-3222-4","article-title":"Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review","volume":"35","author":"Ferriols-Lisart","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2017.07.012_bb0210","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/BOR.0b013e328337b832","article-title":"Patient-tailored therapy in rheumatoid arthritis: an editorial review","volume":"22","author":"Scherer","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0215","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1136\/ard.2010.148015","article-title":"Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response","volume":"70","author":"Emery","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0220","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0230","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.autrev.2010.07.006","article-title":"Predictive factors of response to rituximab therapy in rheumatoid arthritis: what do we know today?","volume":"9","author":"Benucci","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0235","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0240","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/acr.21865","article-title":"Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital","volume":"65","author":"Couderc","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0245","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0250","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.108217","article-title":"The development of assessment of spondyloArthritis international society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0255","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0260","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","article-title":"Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis","volume":"71","author":"Kroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0265","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010952.pub2","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0275","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","article-title":"Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort","volume":"71","author":"Poddubnyy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0280","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0285","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/ard.2006.052878","article-title":"Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0290","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2004.033472","article-title":"Radiographic progression in patients with ankylosing spondylitis after 2years of treatment with the tumour necrosis factor alpha antibody infliximab","volume":"64","author":"Baraliakos","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0295","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","article-title":"Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis","volume":"58","author":"van der Heijde","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0300","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0305","doi-asserted-by":"crossref","DOI":"10.1186\/ar2794","article-title":"Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2years","volume":"11","author":"van der Heijde","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0310","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0315","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1097\/MD.0000000000001170","article-title":"Effectiveness of Adalimumab in non-radiographic axial spondyloarthritis: evaluation of clinical and magnetic resonance imaging outcomes in a monocentric cohort","volume":"94","author":"Cantarini","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0320","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0325","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/MAJ.0b013e3182926a23","article-title":"Efficacy of antitumor necrosis factor(\u03b1) agents on patients with ankylosing spondylitis","volume":"346","author":"Ren","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.autrev.2017.07.012_bb0330","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0335","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.07.012_bb0340","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1007\/s10198-014-0593-5","article-title":"Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis","volume":"15","author":"Baji","year":"2014","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.autrev.2017.07.012_bb0345","doi-asserted-by":"crossref","first-page":"R94","DOI":"10.1186\/ar3369","article-title":"Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study","volume":"13","author":"Arends","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0350","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3years of continuous treatment with infliximab","volume":"7","author":"Baraliakos","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0355","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","article-title":"A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1year: a propensity score-matched cohort study","volume":"75","author":"Z\u00e1vada","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0360","first-page":"174","article-title":"Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice","volume":"33","author":"Arends","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0365","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.autrev.2014.08.029","article-title":"Systemic sclerosis evolution of disease pathomorphosis and survival","volume":"13","author":"Ferri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0370","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.012_bb0375","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2014a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0380","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/ard.2008.103382","article-title":"Prevalence and factors associated with left ventricular dysfunction in the EULAR scleroderma trial and research group (EUSTAR) database of patients with systemic sclerosis","volume":"69","author":"Allanore","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 58","key":"10.1016\/j.autrev.2017.07.012_bb0385","first-page":"S12","article-title":"E\/E' ratio is more sensitive than E\/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis","volume":"28","author":"Lee","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0390","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0395","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.autrev.2015.02.002","article-title":"Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?","volume":"14","author":"Iudici","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0400","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.rdc.2015.04.007","article-title":"Systemic sclerosis: gastrointestinal disease and its management","volume":"41","author":"Gyger","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2017.07.012_bb0405","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","article-title":"Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2014a consensus of systemic sclerosis experts","volume":"42","author":"Walker","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0410","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10103-013-1298-1","article-title":"Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment","volume":"29","author":"Halachmi","year":"2014","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.autrev.2017.07.012_bb0415","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta","year":"2015","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0420","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.06.014","article-title":"Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis","volume":"74","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.012_bb0425","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1741-7015-12-30","article-title":"In-\/off-label use of biologic therapy in systemic lupus erythematosus","volume":"17","author":"Gatto","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0430","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0961203313483376","article-title":"Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis","volume":"22","author":"Davies","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0435","first-page":"449","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian multicentre registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0440","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0445","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.07.012_bb0450","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis. The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0455","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12013-014-0437-z","article-title":"Effect of rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.autrev.2017.07.012_bb0460","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/annrheumdis-2012-201442","article-title":"Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study","volume":"71","author":"Moroni","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0465","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0470","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0475","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0961203309102557","article-title":"Efficacy and safety of infliximab in active SLE: a pilot study","volume":"18","author":"Uppal","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0480","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1177\/0961203313497115","article-title":"Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus\u2014report of 17 cases and review of the literature","volume":"22","author":"Hofmann","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0485","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: a retrospective study of 21 cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0490","series-title":"Abstract no. 3223 presented at the ACR\/ARHP annual meeting, San Francisco, CA, November 6\u201311","article-title":"Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe SLE","author":"Furie","year":"2015"},{"key":"10.1016\/j.autrev.2017.07.012_bb0495","doi-asserted-by":"crossref","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","author":"Rovin","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0500","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.autrev.2014.01.055","article-title":"Optimizing outcome in SLE: treating-to-target and definition of treatment goals","volume":"13","author":"Doria","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0505","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/art.39682","article-title":"Cumulative corticosteroids over 52weeks in patients with systemic lupus erythematosus: pooled analyses from the phase III belimumab trials","volume":"68","author":"van Vollenhoven","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0510","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0515","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2017.07.012_bb0520","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrrheum.2015.88","article-title":"Current treatment of antiphospholipid syndrome: lights and shadows","volume":"11","author":"Espinosa","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0525","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and longterm management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0530","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/BOR.0000000000000200","article-title":"Update on the pathogenesis and treatment of the antiphospholipid syndrome","volume":"27","author":"Chighizola","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0535","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH14-05-0416","article-title":"Diagnosis and management of non-criteria obstetric antiphospholipid syndrome","volume":"113","author":"Arachchillage","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.autrev.2017.07.012_bb0540","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.120576","article-title":"Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study","volume":"40","author":"Del Ross","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0545","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3899\/jrheum.140760","article-title":"Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring?","volume":"42","author":"Clark","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0550","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3899\/jrheum.141407","article-title":"Obstetric antiphospholipid syndrome: lobsters only? Or should we also look for selected red herrings?","volume":"42","author":"Meroni","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0555","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0961203312465782","article-title":"Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management","volume":"22","author":"Alijotas-Reig","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.autrev.2014.08.040","article-title":"Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0565","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1182\/blood-2011-02-339234","article-title":"First-trimester low-dose prednisolone in refractory antiphospholipidantibody-related pregnancy loss","volume":"117","author":"Bramham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2017.07.012_bb0570","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/art.10957","article-title":"Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies","volume":"48","author":"Triolo","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0575","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0002-9378(00)70500-X","article-title":"A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group","volume":"182","author":"Branch","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0580","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijgo.2008.11.010","article-title":"Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome","volume":"104","author":"Dendrinos","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.autrev.2017.07.012_bb0585","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.8755-8920.2001.450309.x","article-title":"Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin","volume":"45","author":"Vaquero","year":"2001","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0590","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.autrev.2011.04.011","article-title":"New autoantigens in the antiphospholipid syndrome","volume":"10","author":"Alessandri","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0595","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0002-9343(96)00060-5","article-title":"Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry","volume":"100","author":"Finazzi","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0600","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.autrev.2012.11.008","article-title":"Correct laboratory approach to APS diagnosis and monitoring","volume":"12","author":"Pengo","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0605","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156407","article-title":"Measuring IgA anti-\u03b22-Glycoprotein I and IgG\/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome","volume":"11","author":"Pericleous","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.012_bb0610","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","article-title":"Sj\u00f6gren's syndrome","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.07.012_bb0615","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","article-title":"Pathogenetic mechanisms in the initiation and perpetuation of Sj\u00f6gren's syndrome","volume":"6","author":"Voulgarelis","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0620","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"76","author":"Shiboski","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0625","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0630","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0635","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0640","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/acr.20173","article-title":"Accurate detection of changes in disease activity in primary Sj\u00f6gren's syndrome by the European League Against Rheumatism Sj\u00f6gren's Syndrome Disease Activity Index","volume":"62","author":"Seror","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0645","doi-asserted-by":"crossref","first-page":"348-5","DOI":"10.1136\/annrheumdis-2014-206418","article-title":"Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients","volume":"75","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0650","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sjogren's syndrome patient reported index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0655","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/keu361","article-title":"Do the EULAR Sj\u00f6gren's syndrome outcome measures correlate with health status in primary Sj\u00f6gren's syndrome?","volume":"54","author":"Lendrem","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0660","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/annrheumdis-2012-eular.3189","article-title":"How good are the EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI), and Eular Sj\u00f6gren's syndrome patients reported index (ESSPRI) in predicting health status in primary Sj\u00f6gren's syndrome?","volume":"71","author":"Ng","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0665","first-page":"510","article-title":"Relationship between disease activity of primary Sjogren's syndrome and patient reported outcome \u2014 data from an interim analysis of the UK primary Sj\u00f6gren's syndrome registry","volume":"70","author":"Ng","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0670","article-title":"Severe health-related quality-of-life impairment in active primary Sj\u00f6gren's syndrome is driven by patient-reported outcomes: data from a large therapeutic trial","author":"Cornec","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0675","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/rheumatology\/ket270","article-title":"The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients","volume":"52","author":"Cho","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0680","first-page":"505","article-title":"Assessment of systemic disease activity is complementary to assessment of patient's symptoms in primary Sjogren's syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0685","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2013.12.010","article-title":"Outcome measures for primary Sj\u00f6gren's syndrome: a comprehensive review","volume":"51","author":"Seror","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.07.012_bb0690","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/annrheumdis-2013-204634","article-title":"The prognostic value of routinely performed minor salivary gland assessments in primary Sj\u00f6gren's syndrome","volume":"73","author":"Risselada","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0695","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","article-title":"Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome","volume":"70","author":"Theander","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0700","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/bcmd.2001.0446","article-title":"Preliminary classification of nonmalignant B cell proliferation in Sjogren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach","volume":"27","author":"De Vita","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0705","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard.2006.052647","article-title":"Progression of salivary gland dysfunction in patients with Sj\u00f6gren's syndrome","volume":"66","author":"Pijpe","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0710","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome","volume":"91","author":"Voulgarelis","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0720","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.20176","article-title":"Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study","volume":"50","author":"Theander","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0725","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","article-title":"Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome","volume":"29","author":"Skopouli","year":"2000","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0730","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome","volume":"46","author":"Ioannidis","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0735","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","article-title":"Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study","volume":"51","author":"Quartuccio","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.07.012_bb0740","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0745","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2017.07.012_bb0750","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1182\/blood-2008-04-149567","article-title":"Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development","volume":"111","author":"De Re","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2017.07.012_bb0755","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/rheumatology\/kem079","article-title":"Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors","volume":"46","author":"Brito-Zeron","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0760","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","article-title":"Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome","volume":"42","author":"Voulgarelis","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.012_bb0765","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keh407","article-title":"Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome","volume":"44","author":"Ramos-Casals","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0770","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","article-title":"Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects","volume":"88","author":"Baimpa","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0775","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.semarthrit.2011.04.006","article-title":"Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome","volume":"41","author":"Solans-Laque","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0780","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.autrev.2015.07.002","article-title":"Anti-SSA\/SSB-negative Sjogren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution","volume":"14","author":"Quartuccio","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2017.07.012_bb0785","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sj\u00f6gren's syndrome: a two year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.autrev.2017.07.012_bb0790","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1177\/096120339600500108","article-title":"Treatment of primary Sj\u00f6gren's syndrome with hydroxychloroquine: a retrospective, open-label study","volume":"5","author":"Fox","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.07.012_bb0795","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.012_bb0800","first-page":"555","article-title":"Moutsopoulos HM methotrexate in primary Sj\u00f6gren's syndrome","volume":"14","author":"Skopouli","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0805","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome","volume":"25","author":"Price","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0810","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/ar2322","article-title":"Mycophenolate sodium treatment in patients with primary Sj\u00f6gren syndrome: a pilot trial","volume":"9","author":"Willeke","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2017.07.012_bb0815","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrrheum.2012.53","article-title":"Topical and systemic medications for the treatment of primary Sj\u00f6gren's syndrome","volume":"8","author":"Ramos-Casals","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0820","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/ncprheum0165","article-title":"The management of Sj\u00f6gren's syndrome","volume":"2","author":"Mavragani","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0825","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of primary Sj\u00f6gren syndrome: a systematic review","volume":"304","author":"Ramos-Casals","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2017.07.012_bb0830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2017.07.012_bb0835","article-title":"Preliminary results of a double-blind randomized trial of rituximab anti-B-cell therapy in patients with primary Sjogrens syndrome (abstract)","volume":"67","author":"Bowman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0840","first-page":"2249","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0845","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0850","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/acr.22052","article-title":"Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sj\u00f6gren's syndrome: a pilot study","volume":"65","author":"Adler","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0855","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1136\/annrheumdis-2013-204653","article-title":"Abatacept treatment reduces disease activity in early primary Sj\u00f6gren's syndrome (open-label proof of concept ASAP study)","volume":"73","author":"Meiners","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0860","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.07.012_bb0865","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.07.012_bb0870","first-page":"490","article-title":"Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy","volume":"32","author":"De Vita","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0875","first-page":"311","article-title":"Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sj\u00f6gren's syndrome: follow-up after the end of the phase II open-label BELISS study","volume":"34","author":"Quartuccio","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0880","first-page":"69","article-title":"The unmet need in rheumatology: reports from the targeted therapies meeting 2016","volume":"34","author":"Winthrop","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0885","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0890","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.autrev.2015.01.004","article-title":"Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease","volume":"14","author":"Ruscitti","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2017.07.012_bb0895","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3899\/jrheum.150088","article-title":"The endothelial-mesenchymal transition in systemic sclerosis is induced by endothelin-1 and transforming growth factor-\u03b2 and may be blocked by macitentan, a dual endothelin-1 receptor antagonist","volume":"42","author":"Cipriani","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0900","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-1536-7-13","article-title":"Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis","volume":"7","author":"Cipriani","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.autrev.2017.07.012_bb0905","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/rheumatology\/keu398","article-title":"Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study","volume":"54","author":"Giacomelli","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.07.012_bb0910","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.autrev.2016.12.006","article-title":"Sj\u00f6gren's syndrome-associated myositis with germinal centre-like structures","volume":"16","author":"Espitia-Thibault","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0915","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.autrev.2014.01.052","article-title":"Unmet needs in the treatment of autoimmunity: from aspirin to stem cells","volume":"13","author":"Chang","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0920","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.autrev.2016.07.035","article-title":"Fc-gamma receptors: attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs","volume":"15","author":"Bosques","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0925","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.autrev.2016.12.003","article-title":"TLRs, future potential therapeutic targets for RA","volume":"16","author":"Elshabrawy","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0930","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2017.03.008","article-title":"Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus and antiphospholipid syndrome: a systematic review","volume":"16","author":"Leone","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0935","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.autrev.2016.12.009","article-title":"A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis","volume":"16","author":"Misra","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0940","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.12667","volume":"182","author":"Ruscitti","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2017.07.012_bb0945","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.autrev.2016.01.006","article-title":"Coexistence of ischemic heart disease and rheumatoid arthritis patients\u2014a case control study","volume":"15","author":"Houri Levi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0950","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12916-016-0738-8","article-title":"Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers","volume":"14","author":"Ruscitti","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2017.07.012_bb0955","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.autrev.2016.09.016","article-title":"Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: analysis of 41 cases collected in 2 rheumatologic centers","volume":"16","author":"Ruscitti","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0960","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.autrev.2017.01.009","article-title":"Subclinical atherosclerosis in systemic lupus erythematosus: comparable risk with diabetes mellitus and rheumatoid arthritis","volume":"16","author":"Tektonidou","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0965","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.autrev.2016.07.026","article-title":"Cardiovascular risk assessment in patients with rheumatoid arthritis: the relevance of clinical, genetic and serological markers","volume":"15","author":"L\u00f3pez-Mej\u00edas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0970","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.autrev.2017.03.012","article-title":"Novel risk factors related to cancer in scleroderma","volume":"16","author":"Bernal-Bello","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0975","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.autrev.2017.03.005","article-title":"Comorbid association of antiphospholipid antibodies and migraine: a systematic review and meta-analysis","volume":"16","author":"Islam","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"10.1016\/j.autrev.2017.07.012_bb0980","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2017.02.003","article-title":"Autoimmune neuropathies associated to rheumatic diseases","volume":"16","author":"Martinez","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.07.012_bb0985","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.autrev.2017.01.012","article-title":"Cardiomyopathy \u2014 an approach to the autoimmune background","volume":"16","author":"Becker","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2017.07.012_bb0990","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170108","article-title":"Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1year prospective single centre study","volume":"12","author":"Ruscitti","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.07.012_bb0995","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00296-014-3196-7","article-title":"Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis","volume":"35","author":"Loza","year":"2015","journal-title":"Rheumatol Int"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217301830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T21:28:48Z","timestamp":1750541328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217301830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":199,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1568997217301830"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}